Abstract
The key factor for the effective treatment of infectious diseases is timely causal treatment [1, 2]. However, due to various reasons, the arsenal of etiotropic drugs for the treatment of congenital infections (CIs) has been significantly small [3–6]. At the same time, in the treatment of bacterial CIs (congenital syphilis, congenital listeriosis, congenital Streptococcus agalactiae infection, congenital chlamydiosis, congenital ureaplasmosis, congenitan mycoplasmosis and other), only some of the effective antibiotics are not safe enough for use in newborns. What is more, until recently, there were practically no etiotropic therapies except Aciclovir for the treatment of viral CIs [2–6]. In view of the fact that cytomegalovirus infection (CMV) is the most common viral CI (in the US, it is diagnosed in 1% of all live births), the absence of etiotropic therapies has been particularly critical for the management of congenital CMV infection [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
